Novartis’ continuing search for new ways to take drugs into the brain has resulted in a $1.7 billion deal with SciNeuro ...

Evogene and Unravel Biosciences are collaborating to use AI to speed the development of therapies that promote myelin sheath ...

The "Blood Brain Barrier Market, 3rd Edition - Industry Trends and Global Forecasts to 2035: Distribution by Type of Molecule, Route of Administration, Target Disease Indication, Therapeutic Area and ...

Johns Hopkins researchers identified a new target for treating Alzheimer’s disease by focusing on a protein that produces tiny amounts of hydrogen sulfide in healthy brain cells.

Swiss drugmaker Novartis has signed a licensing deal worth nearly $1.7 billion with privately held SciNeuro Pharmaceuticals to develop potential antibody treatments for Alzheimer's disease, the ...

A nanomaterial based on a platform developed by Professor Samuel Stupp crosses the blood-brain barrier and targets harmful ...

Getting therapeutic drugs past the blood-brain barrier has long been a major challenge in treating brain diseases. Now, researchers have explored how cholesterol-modified heteroduplex oligonucleotides ...

While this protects the brain from external threats, it also presents a major challenge for treating neurological diseases, as many potentially therapeutic compounds are unable to cross. One potential ...

Scientists have found a new way to transport medicine into the brain, which they hope could lead to improved treatments for diseases such as Alzheimer’s in the future. Experts from Newcastle ...

Drug delivery to the brain remains challenging mainly due to the blood-brain barrier (BBB) that regulates the entrance of substances to the brain.We use a Nanotechnology approach to enhance drug ...